Skip to main content

Advertisement

SpringerLink
Log in

Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs

  • Special Section
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. National Organization for Rare Disorders, Danbury, USA

    Frank J. Sasinowski M.S., M.P.H., J.D. (Chairman of the Board)

Authors
  1. Frank J. Sasinowski M.S., M.P.H., J.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Frank J. Sasinowski is a director with the law firm of Hyman, Phelps & McNamara, P.C. and Chairman of the Board of Directors of the National Organization for Rare Disorders (NORD).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasinowski, F.J. Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs. Ther Innov Regul Sci 46, 238–263 (2012). https://doi.org/10.1177/0092861511435906

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/0092861511435906

Search

Navigation